The present study was designed to assess the pharmacodynamics and the plasma levels of atracurium and laudanosine found during a 72-hour fixed rate infusion of atracurium in acute respiratory distress syndrome patients without renal or liver failure.
Neuromuscular blocking drugs (NMBDs) are widely used in combination with sedative drugs to facilitate mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) [1] [2] [3] . Various NMBDs are used [4] [5] [6] [7] [8] [9] . In studies involving critically ill patients, the use of neuromuscular blockade was heterogeneous in the indications (ARDS, asthma, head, chest or abdominal trauma and other) and in its duration. In these studies, the infusion rate was always adjusted to reach an expected goal of neuromuscular blockade (from one to three responses of the train-of-four (TOF) count) but this goal was reached in 50 to 75% patients [4] [5] [6] [7] [8] [9] . The use of a fixed infusion rate could avoid adjustments of the infusion rate but could lead to an accumulation of NMBD. Atracurium is of particular interest because it undergoes a spontaneous breakdown independently of hepatic and renal functions (Hoffmann elimination) 10 . Therefore, the aim of the present study was to assess the pharmacodynamics of atracurium during a bolus (1 mg.kg -1 ) and a fixed-rate infusion of atracurium (1 mg.kg -1 .h -1 ) given over a 72 h period, and to determine plasma concentrations of atracurium and laudanosine during the infusion in mechanically ventilated patients with ARDS without renal or liver failure.
MATERIALS AND METHODS
After approval from the hospital ethics committee and a written informed consent from each patient's next of kin, patients with ARDS (definition of the American-European consensus conference on ARDS) in whom muscle paralysis could facilitate mechanical ventilation were enrolled into the study 11 . They were sedated (flunitrazepam 1 to 2 mg.h -1 , fentanyl 250 µg.h -1 ) and mechanically ventilated in pressure support mode as usually performed in the unit 12 . Exclusion criteria were: patients <18 years, pregnancy, known sensitivity to NMBDs, a personal or family history of malignant hyperthermia, clinically significant neuromuscular disease, administration of a NMBD during the previous 24 hours, and a personal history of seizures. To avoid confounding influences altering the pharmacodynamics and pharmacokinetics of atracurium, patients with hepatic (serum bilirubin >100 µmol.l -1 ) and/or renal (serum creatinine >150 µmol.l -1 or clearance of creatinine <0.5 ml.s -1 ) dysfunction were also excluded.
Neuromuscular blockade was assessed using an accelerograph (TOF-guard, Biometer, Denmark) 13 . The skin over the ulnar nerve at the wrist was cleansed. Electrodes were applied to allow stimulation of the ulnar nerve at the wrist, using the train-offour (TOF) twitch technique. The transducer was attached to the thumb to measure acceleration in response to contraction of the adductor pollicis muscle. The intensity of stimulation was 60 mA. The accelerograph was able to record the TOF count, the TOF ratio (T4/T1) and the post tetanic count (PTC) if relevant (i.e TOF count=0). The electrodes were changed every day. Neuromuscular blockade was introduced by an intravenous bolus of 1 mg.kg -1 given over three minutes followed by a fixed infusion (1 mg.kg -1 .h -1 ), the patients' weight being measured every second day. This regimen was chosen because the volume of distribution is often increased in critically ill patients 10 . Moreover, a previous study performed in the unit showed that patients requiring muscle paralysis in intensive care units needed larger doses than in anaesthesia 14 . The infusion was stopped after 72 hours to assess the patient's respiratory status. If required, the atracurium infusion was resumed.
Plasma concentrations of atracurium and laudano-sine were measured in each patient. Each arterial blood sample was placed in an EDTA-coated tube and immediately chilled in an ice-water bath. It was centrifuged at 4°C. A 1.0 ml aliquot of plasma was transferred to another tube containing 40 microlitres of 0.5 M sulfuric acid to prevent degradation of atracurium. The plasma sample was frozen at -30°C until assayed. Atracurium and laudanosine plasma concentrations were measured by a specific high-performance liquid chromatographic method coupled with fluorimetric detection 15 . Standard electroencephalography (EEG) using eight electrodes was performed daily during 10 to 15 minutes until two days after the infusion cessation, to detect potential seizure activity induced by laudanosine 16 . The EEGs were read by an electrophysiologist who was informed of the study and the goal of EEG.
In each patient, age, gender, weight, APACHE II and acute lung injury (ALI) scores were recorded 11 . The P a O 2 /F i O 2 ratio was recorded at the onset and at the cessation of infusion. A range of biologic parameters were recorded: serum lactate, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatinine and creatinine clearance. TOF counts were recorded at baseline and during the infusion until neuromuscular recovery. At the cessation of the infusion, the time to neuromuscular recovery (T4/T1 0.7=T rec ) was measured. The plasma concentrations of atracurium and laudanosine were measured from the baseline throughout the study (µg.ml -1 ).
Neuromuscular blockade was assessed at baseline (zero time) and 10, 60 minutes and 24, 48 and 72 hours after the initial bolus. The infusion was stopped at 72 hours. TOF count was measured 5, 10, 15, 20, 30, 60, 90, 120 and 240 minutes after stopping infusion. Plasma concentrations of atracurium and laudanosine were measured from baseline to 240 minutes and 8, 16, 24, 48, 72 and 96 hours after infusion cessation.
RESULTS
From July 1997 to November 1999, 47 patients were admitted into the unit for management of ARDS. In 25 patients, neuromuscular blockade was required. Sixteen patients were excluded because of renal and/or liver failure. Nine patients (seven males) were included. Patients' demographic and biologic data are shown in Tables 1 and 2. Figure 1 shows TOF count and plasma concentrations of atracurium and laudanosine. The TOF count was always 3 responses during the infusion. In five patients with TOF=0, PTC was recorded between 1 and 7. At the cessation of infusion, the P a O 2 /F i O 2 ratio ranged from 239 to 371 mmHg (allowing the infusion to be definitively interrupted) and T4/T1 ratio was 0.7 within 31 to 96 minutes (median=45 minutes). The highest concentrations of atracurium and laudanosine ranged from 3.3 to 5.8 µg.ml -1 (median=4.8 µg.ml -1 ) and from 3 to 20 µg.ml -1 (median=9.25 µg.ml -1 ), respectively. No seizure was recorded on the daily EEGs. Five patients (n 1,2,4,8,9) died. Patients 1 and 9 died from multiple organ failure. Patient 4 died from pulmonary embolism. Patients 2 and 8 died after ICU discharge.
DISCUSSION
In the present study, a fixed infusion rate of atracurium given after an initial bolus provided satisfactory neuromuscular blockade assessed by TOF 3. After a 72 hour infusion period, its cessation led to a neuromuscular recovery within 96 min and plasma concentrations of atracurium quickly decreased. However, the concentrations of laudanosine ranged from 3 to 20 µg.ml -1 but no seizure activity was recorded on the daily EEGs.
In intensive care units, most of the recommendations for the use of NMBDs are based on the extrapolation of data from patients who received NMBDs during anaesthesia 17 . However, the clinical situations classically encountered in ICU patients may alter the effects and the pharmacokinetics of NMBDs 18 . Many questions remain unanswered. No study has demonstrated that the use of NMBDs improves patient's outcome in ICU situations and the exact indication of NMBDs in ICU remains debated 17 . One recent study only showed that neuromuscular blockade with cis-atracurium improved gas exchange in ARDS 19 . The expected levels of neuromuscular blockade ranged from 1 to 3 responses but these expected levels were reached in only 50 to 75% of patients although the infusion rate of NMBDs was adjusted according to the TOF 4-9 . This could be due 20 . The present study involved patients with ARDS and tried to limit confounding factors such as renal and liver failure 1, 2 . The exclusion of patients with renal and liver failure led to low APACHE II scores but the overall mortality (5 patients out of 9) is commonly reported in patients with ARDS. Atracurium was chosen because its breakdown is independent of hepatic and renal functions 10 . Since its metabolite, laudanosine, has a different pharmacokinetic profile in patients with renal failure 18 , patients with renal and liver failure (potential abnormalities in protein synthesis) were excluded to make the patient population more homogeneous. A constant infusion rate was chosen because it avoided dose adaptation and an increase in nurse workload. The duration of infusion chosen was 72 hours because a recent study has shown that gas exchange was improved over this time 12 . That was confirmed in the present study. A bolus (1 mg.kg -1 ) followed by an infusion (1 mg.kg -1 .h -1 ) was chosen because the volume of distribution is often increased in ICU patients 10 . The requirement of larger dose of atracurium than in anaesthesia was reported in previous studies and was previously observed in our unit 4, 7, 9, 14 . Therefore, the present study is the first to report a fixed infusion rate of atracurium in ARDS patients during a constant period. This dose regimen of atracurium provided satisfactory neuromuscular blockade (TOF 3) with a prompt recovery at the cessation of infusion (<100 min). These results are in accordance with previous studies which have reported an infusion rate between 0.29 to 1.2 mg.kg -1 .h -1 and recovery time frequently <90 minutes 4, 7, 9 . The plasma concentrations of atracurium are higher than those reported by Parker which is in keeping with the infusion rates used in this study, which were 66% greater (1 vs 0.6 mg.kg -1 .h -1 ). The average laudanosine concentrations were in accordance with those reported by Parker and Boyd 7, 18 . They were often <10 µg.ml -1 . However, in four patients (patients 1, 2, 3, 9), laudanosine was >10 µg.ml -1 and reached nearly 20 µg.ml -1 in patient 9. In patients 1 and 9, renal function was impaired during the study and anuric renal failure occurred after the cessation of infusion. This may have led to an accumulation of laudanosine 18 . In patients 2 and 3, transient impairment of renal function (oliguria with creatinine >100 µmol.l -1 , quickly reversed) could explain concentration >10 µg.ml -1 (only one value in patient 3). Despite these high concentrations, no seizures were recorded on daily EEGs. A daily EEG was probably insufficient to detect all seizure activities but seizures attributable to laudanosine have only been reported in animal studies 16 . Moreover, sedation with flunitrazepam may have had an anticonvulsant effect.
In a clinical setting, the present study demonstrated that, in sedated and ventilated ARDS patients without renal or liver failure, a fixed infusion rate of atracurium provides efficient neuromuscular blockade with rapid recovery after its cessation. A fixed infusion rate is attractive because it is easily performed and requires no close monitoring and does not increase nurse workload. However, the level of paralysis could be considered excessive but the best level of neuromuscular blockade remains to be determined. Moreover, an accumulation of laudanosine occurred in patients with renal impairment without documented seizure. The results of this study cannot be extrapolated to patients given infusions lasting more than 72 hours who may be at risk of developing neuromyopathy. The latter has been reported with atracurium and aminosteroidal relaxants, often in association with the concomitant use of corticosteroids 10, [21] [22] [23] [24] .
